• Mashup Score: 2

    PURPOSE Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of chemotherapy completion and is associated with cancer mortality. The effect of exercise and eating a healthy diet on RDI is unknown. We conducted a randomized trial of an exercise and nutrition intervention on RDI and pathologic complete response (pCR) in women diagnosed with breast cancer initiating chemotherapy. METHODS One hundred seventy-three women with stage I-III breast cancer were randomly assigned to usual care (UC; n = 86) or a home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians (n = 87). Chemotherapy dose adjustments and delays and pCR were abstracted from electronic medical records. T-tests and chi-square tests were used to examine the effect of the intervention versus UC on RDI and pCR. RESULTS Partici

    Tweet Tweets with this article
    • 🏃‍♀️ Exercise and nutrition led to improved diet quality, physical activity, and pCR in women receiving #chemotherapy for #BreastCancer. ➡️ https://t.co/to4MpmrqFs #BCSM @mirwin_yale https://t.co/GvzzRhPxDX

  • Mashup Score: 0

    The NCCN Best Practices Committee’s June 2023 survey results found that 93% of cancer centers surveyed at that time were experiencing a shortage of carboplatin, and 70% lacked a steady supply of cisplatin. NCCN’s follow-up survey was conducted from September 6 to 27, 2023. “Everyone with cancer should have access to the best possible treatment according to the latest evidence and expert consensus guidelines,” said Robert W. Carlson, MD, Chief Executive Officer of NCCN. “Drug shortages aren’t new, but

    Tweet Tweets with this article
    • Chemotherapy Shortages Ongoing, According to New Survey https://t.co/TO205drlPi #oncology #chemotherapy #drugshortages

  • Mashup Score: 0

    Clinical Trial Summary (S2001) What is the purpose of this clinical trial? This study tests treatment for pancreatic cancer that has spread. It is for people with a BRCA1 or BRCA2 gene change (mutation) that is inherited (passed down in a family). After initial chemotherapy treatment for pancreatic cancer, doctors may…

    Tweet Tweets with this article
    • Olaparib is FDA-approved to treat advanced #pancreatic cancer after initial #chemotherapy for people with BRCA gene mutations. Study S2001 adds pembrolizumab to olaparib for these patients. Learn more at https://t.co/RD8HV4AXah. Or call 1-800-4-CANCER. Ask about S2001. #pancsm https://t.co/OhFtZkTSzM

  • Mashup Score: 0

    Background: Prophylactic growth-factor therapy with granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients with breast cancer initiating myelosuppressive chemotherapy. However, little is known about the protective benefit early in the chemotherapy cycle. Methods: To assess the relationship between G-CSF prophylaxis and incidence of FN/infection in week 1 versus beyond week 1 of the first chemotherapy cycle, a retrospective study was conducted using Medicare claims from 2005 through 2020 among patients with breast cancer initiating high-risk chemotherapy. Two cohorts were compared based on G-CSF prophylaxis within 3 days following chemotherapy initiation. The primary outcome was FN or infection, defined as hospitalization with neutropenia, fever, or infection diagnosis. Secondary outcomes were a stricter definition of FN and infection-related hospitalization. Unadjusted and regression-adjusted proportions of patients experiencing each outc

    Tweet Tweets with this article
    • Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile #Neutropenia and Infection After High-Risk #Chemotherapy: https://t.co/yKSKZr4RUm @BlayneyDouglas @NicoleKuderer @gary_lyman https://t.co/mbMPH6Yy96